As an Amazon Associate I earn from qualifying purchases

A C.D.C. panel will meet today on the Johnson & Johnson vaccine pause.


The committee could recommend that Johnson & Johnson add a formal warning label about the side effect, as the company has done in the European Union. Roughly 10 million doses or more of the vaccine, produced at the company’s factory in the Netherlands, are sitting on shelves across the United States and could be deployed immediately.

The meeting comes as the federal government is also investigating problems at a Baltimore factory that was slated to help satisfy the country’s demand. Emergent BioSolutions, the plant’s operator, has produced tens of millions of doses of Johnson & Johnson’s vaccine, but they cannot be distributed until regulators certify the plant.

After Emergent had to discard up to 15 million possibly contaminated doses of the vaccine last month, federal regulators conducted an inspection that found a series of problems, including the risk that other batches could have been contaminated.

Last week’s pause followed reports of six women who experienced a rare type of blood clot in the brain within three weeks of getting the Johnson & Johnson vaccine. The clots were accompanied by an unusual drop in platelets, components of the blood that normally help heal wounds.

On Thursday, the Oregon health authorities reported that a death was being investigated for a possible connection to the Johnson & Johnson vaccine. The woman who died was in her 50s and had symptoms consistent with the blood clotting cases identified in eight other Johnson & Johnson recipients in the U.S. Dr. Shimi Sharief, the state health authority’s senior health adviser, emphasized that it was not known whether the woman’s death was related to the vaccine.



Source link

We will be happy to hear your thoughts

Leave a reply

ATLION FITNESS
Reset Password
Compare items
  • Total (0)
Compare
0